Sino Biopharmaceutical Limited (1177.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
24379
First IPO Date
December 08, 2003
| Name | Title | Pay | Year Born |
| S. Y. Tse | Chief Executive Officer & Executive Director | 74.68M | 1996 |
| Toogood Ben | Chief Executive Officer of InvoX & Head of Globalization | 0 | 1977 |
| Zhoushan Tian | Executive Director | 2.16M | 1964 |
| Hsin Tse | Senior Vice President & Executive Director | 5.31M | 1970 |
| Y. Y. Tse | Executive Chairwoman of the Board | 42.67M | 1992 |
| Cheung Ling Cheng | Executive Vice Chairwoman of the Board | 45.59M | 1964 |
| Ping Tse | Founder & Senior Executive Vice Chairman | 51.97M | 1952 |
| Rongjun Liu | Head of Clinical Development for Autoimmune Diseases | 0 | N/A |
| Kuen Lai | Company Secretary | 0 | N/A |
| Chun Ling Li | Chief Financial Officer | 0 | 1972 |
| Xiaoyan Kang | Chief Medical Officer | 0 | 1976 |
| Meng Liu | Head of Clinical Development for Chronic Diseases | 0 | N/A |
| Song Jin | Vice President of Public Affairs & ESG | 0 | 1976 |
Established in 2000 and headquartered in Wan Chai, Hong Kong, Sino Biopharmaceutical Limited functions as an investment holding entity overseeing a prominent research and development-focused pharmaceutical conglomerate. Its core operations are primarily situated within the People's Republic of China, segmented into three main areas: modern and traditional Chinese medicines and chemical pharmaceuticals, investment ventures, and other diverse activities. The company maintains an extensive portfolio of pharmaceutical products addressing numerous therapeutic categories. This includes oncology treatments such as Qingkeshu tablets and Anxian capsules; cardiovascular and cerebrovascular medications like Kaina and Anrixin tablets; hepatitis remedies, including Tianqingganmei injections; and orthopedic solutions such as Gaisanchun capsules. The product range also covers respiratory system drugs, parenteral nutritional therapies (e.g., Xinhaineng injections), and other miscellaneous medicines like Tuotuo tablets. Furthermore, Sino Biopharmaceutical distributes a selection of advanced pharmaceuticals, including Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. Beyond pharmaceutical manufacturing and distribution, the company engages in a broad array of healthcare-related services and investments. These activities encompass managing property assets, retailing and distributing pharmaceutical goods, offering optometry services and selling ophthalmic products, and operating hospitals. It also provides medical management and health information consultancy, bio-tech transfer and advisory services, and manufactures and markets health food products. Additionally, the company performs orthopedic outpatient and surgical procedures, develops medical and health technologies, trades optical glasses, and conducts research, development, and sales of medical devices and active pharmaceutical ingredients.